ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations
Insider Trading
ADMA Biologics faces a federal securities lawsuit alleging revenue inflation through channel stuffing and concealed distribution relationships.Summary
ADMA Biologics, Inc. (NASDAQ:ADMA) is currently navigating a complex landscape of analyst optimism and significant legal challenges. On June 10, 2026, Raymond James analyst Ryan Deschner initiated coverage with an
(Source：Insider Trading)